ReviewViruses2014
Virus-vectored influenza virus vaccines.
Review in Viruses, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Highly efficient intranasal H5N1 vaccine based on a safe vesicular stomatitis virus (VSV) vector.Signal transduction and targeted therapy · 2026Article
- Inflammatory conditions shape phenotypic and functional characteristics of lung-resident memory T cells in mice.Nature communications · 2025Article
- Development of an AlphaLISA assay for sensitive and accurate detection of influenza B virus.Frontiers in medicine · 2023Article
- Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms.Vaccines · 2022Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Article
- Influenza Vaccine: An Engineering Vision from Virological Importance to Production.Biotechnology and bioprocess engineering : BBE · 2022Review
- COVID-19 vaccine platforms: Delivering on a promise?Human vaccines & immunotherapeutics · 2021Review
- Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.Journal of pharmaceutical analysis · 2020Review
- Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fcγ receptor-activating antibodies.EMBO molecular medicine · 2020Article
- Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now?Vaccines · 2020Article
- Priorities for developing respiratory syncytial virus vaccines in different target populations.Science translational medicine · 2020Review
- Current and Novel Approaches in Influenza Management.Vaccines · 2019Review
- Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs.Vaccine · 2019Article
- Immunity to Respiratory Infection Is Reinforced Through Early Proliferation of Lymphoid TFrontiers in immunology · 2019Article
- Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of View.Vaccines · 2018Review
- Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets.Human vaccines & immunotherapeutics · 2017Article
- Development of respiratory syncytial virus (RSV) vaccines for infants.The Journal of infection · 2017Review
- Review
- Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the availability of an inactivated vaccine that has been licensed for >50 years, the influenza virus continues to cause morbidity and mortality worldwide. Constant evolution of circulating influenza virus strains and the emergence of new strains diminishes the effectiveness of annual vaccines that rely on a match with circulating influenza strains. Thus, there is a continued need for new, efficacious vaccines conferring cross-clade protection to avoid the need for biannual reformulation of seasonal influenza vaccines. Recombinant virus-vectored vaccines are an appealing alternative to classical inactivated vaccines because virus vectors enable native expression of influenza antigens, even from virulent influenza viruses, while expressed in the context of the vector that can improve immunogenicity. In addition, a vectored vaccine often enables delivery of the vaccine to sites of inductive immunity such as the respiratory tract enabling protection from influenza virus infection. Moreover, the ability to readily manipulate virus vectors to produce novel influenza vaccines may provide the quickest path toward a universal vaccine protecting against all influenza viruses. This review will discuss experimental virus-vectored vaccines for use in humans, comparing them to licensed vaccines and the hurdles faced for licensure of these next-generation influenza virus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.